A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, an Intravenous Fenretinide Phospholipid Suspension (12.5 mg/mL)

IF 7.1 1区医学 Q1 ONCOLOGY

European Journal of Cancer Pub Date : 2025-10-01 DOI:10.1016/j.ejca.2025.115879

Oleg E. Akilov, Auris O. Huen, Barbara Pro, Dipenkumar Modi, Ann F. Mohrbacher, Brad M. Haverkos, Aaron R. Mangold, Christiane Querfeld, Ryan A. Wilcox, Louis M. Scarmoutzos, Michael Burns, Earle T. Holsapple, Kenneth D. Massey, Ralph E. Parchment, Yamini Donekal, Ali Moiin

引用次数: 0

查看原文本刊更多论文

一项针对复发/难治性t细胞非霍奇金淋巴瘤的1a/1b期试验，以确定ST-001的安全性、药理学和最大耐受剂量，ST-001是一种静脉注射芬瑞啶脂混悬液（12.5 mg/mL）

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Cancer 医学-肿瘤学

CiteScore

11.50

自引率

4.80%

发文量

953

审稿时长

23 days

期刊介绍： The European Journal of Cancer (EJC) serves as a comprehensive platform integrating preclinical, digital, translational, and clinical research across the spectrum of cancer. From epidemiology, carcinogenesis, and biology to groundbreaking innovations in cancer treatment and patient care, the journal covers a wide array of topics. We publish original research, reviews, previews, editorial comments, and correspondence, fostering dialogue and advancement in the fight against cancer. Join us in our mission to drive progress and improve outcomes in cancer research and patient care.